Mobile

A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanav...

Update Il y a 5 ans
Reference: EUCTR2012-005114-20

A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanavir with Truvada® or ritonovir and atazanavir with Truvada® can safely switch to E/C/F/TAF STR without increasing the amount of HIV-1 in their blood

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is: • To evaluate the non-inferiority of switching to a TAF-Containing STR relative to maintaining TDF-Containing Regimens in Virologically-Suppressed HIV-1 positive subjects as determined by having HIV-1 RNA < 50 copies/mL at Week 48 (FDA Snapshot Analysis).

Inclusion criteria

  • Human Immunodeficiency Virus (HIV-1) Infection

Links